Introduction
Prostate cancer is the most prevalent form of malignancy in men in the Western world (Landis et al., 1998) . Previous studies have demonstrated multiple alterations of tumor suppressor genes in human prostate cancers, including the p53 on 17q (Isaacs et al., 1991; Eert et al., 1992) , PTEN1 (Li et al., 1997) and Mxi-1 (Eagle et al., 1995) on 10q and/or Kai-1 on 11p (Dong et al., 1995) genes. Losses of heterozygosity at polymorphic loci on additional chromosomes 8p, 10p, 16q and 18q were also reported, suggesting the involvement of unidenti®ed tumor suppressor genes (Carter et al., 1990; Kunimi et al., 1991; Bova et al., 1993; MacGrogan et al., 1994; Phillips et al., 1994; Brothman et al., 1995; Visakorpi et al., 1995; Ittman, 1996; Trybus et al., 1996) . Cytogenetic studies have con®rmed that the loss of chromosome 10p occurs in some prostate cancers (Brothman et al., 1990; Macoska et al., 1993) .
Transfer of a normal human chromosomal fragment into cancer cells by microcell-mediated chromosome transfer (MMCT), provides an alternative approach to detecting the presence of tumor suppressor genes by testing the ability of normal genes to suppress the malignant phenotype (Weissman et al., 1987; Tanaka et al., 1991) . In prostate cancers, a number of human chromosomes, including 7q (Nihei et al., 1999) , 8q Nihei et al., 1996) , 10q (Nihei et al., 1995) , 11q (Ichikawa et al., 1992; Rinker-Schaeer et al., 1994; Kawana et al., 1997) , 17q (Rinker-Schaeer et al., 1994; Murakami et al., 1995) and 19p (Gao et al., 1999) , have been demonstrated to have suppressor activity for metastasis or tumorigenicity when introduced into rat or human prostate cancer cell lines. Sanchez et al. (1996) reported tumor suppression and cellular apoptosis on introduction of 10p into a prostate cancer cell line, PC-3. We have also demonstrated that transfer of a more restricted region of 17 cM on 10p13 ± 15 into a human prostate cancer cell line, PPC-1, caused a decrease in tumorigenicity in athymic nude mice . Then, we constructed a series of human ± rodent hybrid cells carrying various single transferable fragments (STFs) of 10p tagged with neomycin resistance gene to provide resources for ®ne mapping of the genes on 10p14 ± pter (Murakami, et al., 2000) .
In the present study, we further localized a prostate tumor suppressor gene to a segment of approximately 1.2 Mb on 10p15.1 by functional complementation through MMCT using series of these hybrid cells.
Results
Transfer of human chromosome 10 into PPC-1 cells PPC-1 cells, established from a primary human prostate adenocarcinoma, show strong tumorigenicity when injected subcutaneously into athymic nu/nu mice (Brothman et al., 1991) . Karyotype analysis revealed that one chromosome 10 was completely lost and the other was translocated to chromosomes 1 and 3 and reduplicated (Brothman and Patel, 1992) . LOH analysis con®rmed that all the polymorphic loci examined on chromosome 10 were hemizygous in PPC-1 cells . We have previously mapped tumor suppressor activity of PPC-1 cells to a fragment of 17 cM on 10p13 ± 15¯anked by D10S1172 and D10S506 through MMCT . In order to localize the tumor suppressor gene further by functional complementation, a series of hamster ± human hybrid cells carrying distinct STFs on 10p14 ± 15 were prepared previously (Murakami et al., 2000) . Five of the hybrid cells, C10D5, C10E1, C10D6, C10C4 and C10C7, each containing various portions of the 10p fragment de®ned by STS markers D10S1172 and D10S506, as well as C10B7, were used as donor cells for MMCT into PPC-1 cells (Figure 1a ).
Three to six hybrid cells derived from PPC-1 were obtained after selection of G418 in each MMCT of six distinct STFs. Transfer of chromosomal fragment 10 was con®rmed by¯uorescence in situ hybridization analysis. A representative result is shown in Figure 2 . P10D4-3 was a hybrid cell obtained by transfer of a STF on 10p14 ± 15 from a hamster ± human hybrid cell, C10D4, to PPC-1 cell. When DNA from a BAC clone containing a STS sequence, D10S1779, was used as a probe, three signals were detected, indicating that P10D4-3 carried an exogenous copy of 10p in addition to two copies of endogenous chromosome 10.
Tumorigenicity of hybrid cells
To assess the malignant phenotype of these PPC-1 derived hybrid cells, six of them obtained from independent MMCT of distinct STFs, were analysed for tumorigenicity. Hybrid cells as well as parental PPC-1 cells (5610 4 ) were injected subcutaneously into male BALB/c nu/nu mice. PPC-1 cells formed tumors at 15 of 16 injection sites within 7 weeks, which continued to grow as shown in Figure 3 . Two of the six hybrid cells, P10C7-4 and P10B7-1 also developed tumors at high incidence (six of eight injection sites in each hybrid). The growth rate of these tumors was almost comparable to that of PPC-1 cells (Figure 3 ). In contrast, the other four hybrid cells, P10E1-2, P10D6-4, P10D4-3 and P10D5-4, formed tumors at only one of eight, two of eight, two of 12 and one of 12 injection sites, respectively, at 12 weeks after injection. These tumors grew slower than those of PPC-1 or the former two hybrid cells (Figure 3 ).
Structural analysis of the fragment of chromosome 10 retained in each hybrid
The chromosomal fragments retained in each hybrid cell were con®rmed to determine the region harboring the putative tumor suppressor gene. Polymorphic STS markers mapped on 10p were used to distinguish the transferred, exogenous chromosome 10 from the endogenous chromosomes 10 of PPC-1. Since all 10p fragments in a series of human ± rodent hybrid cells used as donors for MMCT were originally derived from a hamster ± human hybrid cell, HA(10)A, genotypes of transferred chromosomes in the hybrid cells were identical to that of HA (10)A (Pershouse et al., 1993; Murakami et al., 2000) . Representative results of PCR-based analysis using these markers are shown in Figure 4a . DNA fragments containing two markers on 10p, D10S1779 and D10S1720, ampli®ed from PPC-1 and HA(10)A cells showed length polymorphisms. In the analysis of D10S1779, DNA fragments derived from HA(10)A cells were ampli®ed in four hybrid clones, P10E1-2, P10D6-4, P10D4-3 and P10D5-4, indicating transfer and retention of the chromosomal region containing the D10S1779 locus. On the other hand, the fragments containing D10S1720 derived from HA(10)A cells were retained only in two hybrid cells, P10E1-2 and P10D6-4.
Sixteen informative STS markers on 10p and a marker D10S1134 on 10q25 were analysed similarly. As summarized in Figure 1b , all the hybrid cells except for P10D5-4 contained only one continuous 10p fragment (STF). A chromosomal fragment on 10p15
anked by D10S1172 and D10S1720 was commonly retained in the three hybrid cells showing decreased tumorigenicity (P10E1-2, P10D6-4 and P10D4-3), as well as in another suppressed cell, P10D5-4, carrying discontinuous 10p fragments.
Further localization of tumor suppressor genes based on the information of STFs DNA sequence containing a polymorphic STS marker D10S226 from PPC-1 and HA(10)A cells did not show length polymorphism (data not shown). However, absence of a STS sequence D10S226 in P10D4-3 cells was clearly demonstrated by PCR-based analysis of the hamster ± human hybrid cells, C10D4, from which the exogenous 10p fragment in P10D4-3 cells was derived. As shown in Figure 4b , the DNA sequences of D10S226 and D10S1720 were not present while those of D10S1172 and of D10S1779 were present in C10D4 cells. Thus, the region retained among the four suppressed hybrid cells was narrowed down to the fragment¯anked by D10S1172 and D10S226 ( Figure  1b) . Mapping information based on Radiation Hybrid 99 GB4 released from NCBI and Stanford G3 Radiation Hybrid Panel showed that the distance between the two markers, D10S1172 and D10S226 was 4.6 cR. As 1 cR corresponds to approximately 270 kb in this hybrid map, the putative prostate tumor suppressor gene could be mapped to within a fragment of approximately 1.2 Mb on 10p15.1.
Discussion
Two independent studies have demonstrated that the introduction of chromosomal fragment 10p suppressed the tumorigenicity of human prostate cancer cell lines (Sanchez et al., 1996; Murakami et al., 1996) . These ®ndings could provide direct evidence for the presence of tumor suppressor genes on 10p. The relevant genes were subsequently located on chromosome 10pter-q11 or a fragment of 17 cM on 10p13-15, respectively. It is still quite hard, however, to identify the tumor suppressor gene from among the many candidates in these relatively large chromosomal regions. Identi®ca-tion of a gene would be even more dicult when multiple discontinuous chromosomal fragments are retained in recipient cells on MMCT.
Single transferable fragments (STFs) tagged with the neomycin resistance gene, initially reported by Koi et al. (1993) on chromosome 11p, help to overcome these problems. We have previously constructed a series of rodent ± human hybrid cells containing various portions of chromosome 10p (Murakami et al., 2000) and used six hybrids in this study. These STFs are structurally re®ned and successfully transferred into PPC-1 as a single continuous fragment except for one hybrid cell, P10D5-4. It was, therefore, possible to narrow down the candidate region harboring the tumor suppressor gene from a fragment of 17 cM in the previous study to that of approximately 1.2 Mb. The retention of transferred chromosome in PPC-1 derived hybrid cells was directly con®rmed using polymorphic markers. Moreover, the presence or absence of any STS sequence could be determined based on the structural information of the STF in the rodent ± human hybrid. As shown in Figure 4b , D10S226 was not present in P10D4-3 cells as determined from its absence in microcell donor, C10D4 cells. This analysis could exclude a fragment of approximately 1.3 Mb¯anked by D10S226 and D10S1720 from the candidate region.
The malignant phenotype of PPC-1 cells was judged by tumorigenicity in nude mice. Although tumor formation was not completely suppressed in four hybrid cells (P10E1-2, P10D6-4, P10D4-3 and P10D5-4), the suppression appeared to be signi®cant, because the incidence of tumors was decreased, latency was prolonged and the size of tumors that did appear was decreased compared with those of PPC-1 cells or the other four derivatives. On the other hand, the morphology and growth rate in vitro were not aected in the four suppressed cells consistent with our previous ®ndings . In this regard, the introduction of 10p into another prostate cancer cell line, PC-3, was reported to cause cell death in low density cultures in vitro (Sanchez et al., 1996) . Androgen-responsive prostate cancers as well as secretory epithelium of prostate characteristically undergo apoptosis in response to androgen deprivation. Since PC-3 is an androgen independent prostate cancer cell line, the relevant gene on 10p might have restored the cell death pathway in PC-3 cells. Growth of PPC-1 cells is also shown to be androgen independent (Brothman, 1989) . However, we did not see apoptotic cell death in vitro in the four suppressed PPC-1 derived cells (data not shown), although apoptosis in vivo might be partly responsible for their less tumorigenic phenotype. A gene on 10p identical to that reported by Sanchez et al. (1996) might confer distinct phenotypes on PPC-1 cells. Alternatively, a dierent gene could be involved in tumor suppression of PPC-1 cells.
We localized tumor suppressor activity on 10p15.1 by functional complementation. Several independent studies on LOH demonstrated that 10p15 was often deleted in prostate tumors, suggesting that the possible suppressor gene shown in this study was really involved in primary human tumors (Brothman et al., 1990; Carter et al., 1990; Bergerheim et al., 1991) . On the other hand, Trybus et al. (1996) reported that the chromosomal region 10p11.2 was also deleted frequently in 35 human prostate tumors, suggesting the presence of another tumor suppressor gene. The fragment 10p11.2, however, was not included in the candidate region of 17 cM on 10p13-p15 in our previous study . Transfer of STFs containing 10p11.2 into PPC1 cells followed by the comparison of tumor suppressor activity with that of 10p15.1 could clarify possible involvement of two distinct suppressor genes on 10p in human prostate cancers. LOH on 10p has been reported much more frequently in advanced prostate cancers than in clinically localized tumors (Ittmann, 1996) . This ®nding suggests that a putative suppressor gene on 10p is involved in the progression of prostate cancers.
LOH on 10p was also observed in primary human gliomas and glioma-derived cell lines (Steck et al., 1995; Sonoda et al., 1996; Kimmelman et al., 1996) . We have previously demonstrated that transfer of chromosomal fragment 10p containing the commonly deleted regions de®ned by LOH analysis could suppress the malignant phenotype of a human glioblastoma cell line (Kon et al., 1998) . Robertson et al. (1999) also mapped a putative tumor suppressor gene in human melanomas to chromosomal fragment 10p using combinatorial analyses of LOH in primary tumors and functional complementation through transfer of 10p. The candidate regions of glioma or melanoma suppressor genes determined in these studies at least partly overlapped with that identi®ed in this study on prostate cancer, suggesting that an identical gene on 10p is involved in these human tumors.
Further functional complementation including YAC transfer coupled with sequencing analysis of this chromosomal region could lead to the identi®cation of this putative tumor suppressor gene.
Materials and methods

Cell lines
The mouse-human microcell hybrid HA(10)A, carrying a whole human chromosome 10 tagged with neomycinresistance gene as its only human chromosomal material, was obtained from Coriell Cell Repositories (Pershouse et al., 1993) . Six hamster ± human microcell hybrids each containing a portion of 10p were constructed by transfer of irradiated chromosome 10 from HA(10)A into Chinese hamster ovary (CHO) cells (Murakami et al., 2000) . These cell lines were grown in DMEM with high glucose, supplemented with 10% fetal bovine serum and 200 mg/ml G418 (Life Technologies, Inc.). The recipient cell, PPC-1 (Brothman et al., 1989) , was a gift from Dr AR Brothman of the University of Utah, and grown in RPMI 1640 medium with 10% fetal bovine serum, supplemented with 1% penicillin and 1% streptomycin.
Microcell-mediated chromosome transfer and fusion
Microcell-mediated chromosome transfer was performed essentially as described (Fournier, 1981) . Microcells were prepared by treating the donor cells with 0.06 mg/ml of colcemide (Sigma) for 48 h and then exposing them to 10 mg/ ml of cytochalasin B (Sigma) for 30 min. After selection for size through two sterile ®lters (0.8 and 0.5 mm) (Nucleopore), enriched microcells were fused with recipient PPC-1 cells. Hybrid cells were selected against 500 mg/ml of G418.
FISH analysis
FISH was performed as described previously (Pinkel et al., 1986) . Puri®ed BAC DNA was labeled with Spectrum Orange-dUTP (VYSIS) using a nick translation kit (Boehringer Mannheim) and directly used as probe to detect the integrated BAC DNA (Shimura et al., 1999) . After hybridization, cells and chromosomes were counterstained with 4', 6-diamidino-2-phenylindole (DAPI) in an antifade solution composed of 0.1% p-phenylenediamine and 90% glycerol (Wako Pure Chemicals). Digital images were captured using a¯uorescent microscope (Olympus) and analysed with CytoVision (Applied Imaging). In all cases, a minimum of 20 metaphase nuclei were examined.
Tumorigenicity assay
Suspensions of 5610 4 cells in volumes of 0.2 ml PBS were injected subcutaneously into 5-to 6-week-old male BALB/c athymic nu/nu mice (Japan Crea Laboratory). Tumor growth was determined by measuring the xenografts in three dimensions. Volume (V) was determined using the equation V=(L6W6H)60.5, (V, volume; L, length; W, width and H, height). The mice were monitored at least twice a week. All animal experiments were performed in accordance with institutional guidelines.
Analysis with STS markers
DNA was extracted from approximately 10 7 cells in culture by proteinase K-phenol-chloroform extraction (Blin and Staord, 1976) . DNA segments containing STS markers on chromosome 10 were ampli®ed by PCR essentially as described (Albertsen et al., 1994) . The nucleotide sequences of the primers used for PCR were obtained from the Genome Data Base. The 5' end of one of each primer pair was labeled with 32 P-ATP by polynucleotide kinase (Boehringer Mannheim). PCR products were separated on denaturing gels containing 5% acrylamide and 40% urea and autoradiographed at 7808C for 4 ± 12 h on BioMax Film (Kodak) with an intensifying screen.
